{"id":3217,"date":"2013-07-11T06:30:00","date_gmt":"2013-07-11T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/delarsrapport-januari-juni-2013\/"},"modified":"2013-07-11T06:30:00","modified_gmt":"2013-07-11T06:30:00","slug":"delarsrapport-januari-juni-2013","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-juni-2013\/","title":{"rendered":"Del\u00e5rsrapport januari\u2013juni 2013"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>Studien i\u00a0USA fulltalig och goda kliniska resultat presenterade p\u00e5 patienter utanf\u00f6r USA<\/strong><\/div>\n<p>V\u00c4SENTLIGA H\u00c4NDELSER UNDER ANDRA KVARTALET<\/p>\n<p>\u2022 Alla de planerade 42 + 42 patienter har nu inkluderats i den kliniska studien med STEEN Solution\u2122 i USA och de kliniska resultaten \u00e4r mycket lovande.<\/p>\n<p>\u2022 Tre ledande kliniker utanf\u00f6r USA (Toronto, Paris och Europas st\u00f6rsta lungtransplantationsklinik i Wien) presenterade vid ISHLT:s konferens i april mycket goda kliniska data p\u00e5 112 patienter med anv\u00e4ndande av XVIVO Perfusions produkt STEEN Solution\u2122. Resultaten visar att klinikerna genom att anv\u00e4nda STEEN Solution\u2122 kunnat r\u00e4dda m\u00e5nga lungor som initialt bed\u00f6mts som oanv\u00e4ndbara. Lungorna transplanterades till beh\u00f6vande patienter med minst lika goda resultat som de lungor som blivit godk\u00e4nda initialt.<\/p>\n<p>\u2022 FDA:s kompletterande fr\u00e5gor r\u00f6rande ans\u00f6kan om marknadsgodk\u00e4nnande f\u00f6r STEEN Solution\u2122 p\u00e5 den amerikanska marknaden besvarades under kvartalet. FDA ber\u00e4knas komma med besked under det tredje kvartalet.<\/p>\n<p>\u2022 Vid slutet av juni har sammanlagt 47 patienter i USA blivit transplanterade med lungor som gjorts tillg\u00e4ngliga genom anv\u00e4ndning av Steen Solution\u2122 och XVIVOs perfusionsmaskin XPS\u2122.<\/p>\n<p>F\u00d6RSTA HALV\u00c5RET (JAN-JUN 2013)<\/p>\n<p>\u2022 Oms\u00e4ttnings\u00f6kningen var 21 procent i lokala valutor. F\u00f6rs\u00e4ljningen uppgick till 32,1 MSEK (27,8*), motsvarande en \u00f6kning om 15 procent i SEK.<\/p>\n<p>\u2022 R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) uppgick till 6,1 MSEK (9,2*) motsvarande en EBITDA marginal om 19 procent.<\/p>\n<p>\u2022 Nettoresultatet uppgick till 4,1 MSEK, vilket gav ett resultat per aktie om 0,21 SEK.<\/p>\n<p>\u2022 Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten var 7,9 MSEK.<br \/><span><span><span><br \/><\/span><\/span><\/span><\/p>\n<p>ANDRA KVARTALET (APR-JUN 2013)<\/p>\n<p>\u2022 Oms\u00e4ttnings\u00f6kningen var 18 procent i lokala valutor. F\u00f6rs\u00e4ljningen uppgick till 15,8 MSEK (14,0*), motsvarande en \u00f6kning om 12 procent i SEK.<\/p>\n<p>\u2022 R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) uppgick till 2,4 MSEK (4,2*) motsvarande en EBITDA marginal om 15 procent.<\/p>\n<p>\u2022 Nettoresultatet uppgick till 1,7 MSEK, vilket gav ett resultat per aktie om 0,09 SEK.<\/p>\n<p>\u2022 Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten var 3,9 MSEK.<\/p>\n<\/p>\n<p>TELEFONKONFERENS<\/p>\n<p>VD Magnus Nilsson presenterar rapporten vid en telefonkonferens klockan 14:00 torsdagen den 11 juli 2013<br \/>Telefon: 08-50336434, ange kod 98290392<\/p>\n<p><span><span><\/span><\/span><br \/><span>* J\u00e4mf\u00f6relsetal 2012 \u00e4r Vitrolifes segment Transplantation s\u00e5 som det redovisats i Vitrolifes rapportering.<\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n<p><span>Magnus Nilsson, VD, tel: 031-788 21 50, e-post: <a href=\"mailto:magnus.nilsson@xvivoperfusion.com\" rel=\"nofollow\">magnus.nilsson@xvivoperfusion.com<\/a><\/span><br \/><span>Christoffer Rosenblad, CFO, tel: 031-788 21 59, e-post: <a href=\"mailto:christoffer.rosenblad@xvivperfusion.com\" rel=\"nofollow\">christoffer.rosenblad@xvivoperfusion.com<\/a><br \/>F\u00f6r ytterligare information om Xvivo Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, <a href=\"http:\/\/www.xvivoperfusion.com\" rel=\"nofollow\">www.xvivoperfusion.com<\/a><\/span><\/p>\n<p><span>Xvivo Perfusion\u00a0\u00e4r skyldigt att offentligg\u00f6ra informationen i detta pressmeddelande enligt lagen om v\u00e4rdepappersmarknaden och\/eller lagen om handel med finansiella instrument. Informationen l\u00e4mnades f\u00f6r publicering den\u00a011\u00a0juli 2013 kl. 08:30.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Studien i\u00a0USA fulltalig och goda kliniska resultat presenterade p\u00e5 patienter utanf\u00f6r USA V\u00c4SENTLIGA H\u00c4NDELSER UNDER ANDRA KVARTALET \u2022 Alla de&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3217","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q2","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Del\u00e5rsrapport januari\u2013juni 2013 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-juni-2013\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Del\u00e5rsrapport januari\u2013juni 2013 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Studien i\u00a0USA fulltalig och goda kliniska resultat presenterade p\u00e5 patienter utanf\u00f6r USA V\u00c4SENTLIGA H\u00c4NDELSER UNDER ANDRA KVARTALET \u2022 Alla de...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-juni-2013\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-juni-2013\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-juni-2013\\\/\",\"name\":\"Del\u00e5rsrapport januari\u2013juni 2013 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2013-07-11T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-juni-2013\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-juni-2013\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-juni-2013\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Del\u00e5rsrapport januari\u2013juni 2013\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Del\u00e5rsrapport januari\u2013juni 2013 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-juni-2013\/","og_locale":"en_US","og_type":"article","og_title":"Del\u00e5rsrapport januari\u2013juni 2013 - XVIVO","og_description":"Studien i\u00a0USA fulltalig och goda kliniska resultat presenterade p\u00e5 patienter utanf\u00f6r USA V\u00c4SENTLIGA H\u00c4NDELSER UNDER ANDRA KVARTALET \u2022 Alla de...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-juni-2013\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-juni-2013\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-juni-2013\/","name":"Del\u00e5rsrapport januari\u2013juni 2013 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2013-07-11T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-juni-2013\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-juni-2013\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-juni-2013\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Del\u00e5rsrapport januari\u2013juni 2013"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}